Department of Medicine, Duke University, Durham, NC, USA.
Leuk Lymphoma. 2012 Nov;53(11):2326-9. doi: 10.3109/10428194.2012.698276. Epub 2012 Jul 9.
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the United States with almost 4390 attributable deaths per year. Epidemiologic data compiled by the Surveillance, Epidemiology and End Results (SEER) program identifies important differences in incidence and survival for African Americans with CLL. Although the incidence of CLL is lower among African Americans than among Caucasians (4.6 and 6.2 per 100 000 men, respectively), age-adjusted survival is inferior. African American patients with CLL are almost twice as likely to die from a CLL-related complication in the first 5 years after diagnosis as are Caucasian patients with CLL. The biologic basis for these observations is almost entirely unexplored, and a comprehensive clinical analysis of African American patients with CLL is lacking. This is the subject of the present review.
慢性淋巴细胞白血病(CLL)是美国最常见的白血病,每年归因于该病的死亡人数约为 4390 人。监测、流行病学和最终结果(SEER)计划汇编的流行病学数据确定了非裔美国人 CLL 的发病率和存活率存在重要差异。尽管 CLL 在非裔美国人中的发病率低于白种人(男性分别为每 100000 人 4.6 和 6.2),但经过年龄调整后的存活率较低。在诊断后的前 5 年,非裔美国 CLL 患者死于 CLL 相关并发症的可能性几乎是白种人 CLL 患者的两倍。这些观察结果的生物学基础几乎完全未被探索,并且缺乏对非裔美国 CLL 患者的全面临床分析。这是本综述的主题。